VEGFA and Miyoshi myopathy: The Food and Drug Administration (FDA) approved Thalidomide for the treatment of Erythema Nodosum Leprosum (ENL) in 1998 and of Multiple Myeloma (MM) in 2006 because the compound was shown to inhibit angiogenesis through VEGF downregulation (Kenyon et al., 1997; Komorowski et al., 2006).